- Home
- TGTX
TGTX
TG Therapeutics Inc.
as of 12-05-2025 3:44pm EST
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 5.5B | IPO Year: | 1995 |
| Target Price: | $54.75 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.28 - $46.48 | Next Earning Date: | 11-03-2025 |
| Revenue: | $531,898,000 | Revenue Growth: | 100.88% |
| Revenue Growth (this year): | 82.31% | Revenue Growth (next year): | 49.05% |
AI-Powered TGTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of TG Therapeutics Inc. (TGTX)
Director
Avg Cost/Share
$32.57
Shares
5,000
Total Value
$162,850.00
Owned After
223,816
SEC Form 4
Director
Avg Cost/Share
$32.24
Shares
20,852
Total Value
$672,268.48
Owned After
94,061
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Echelard Yann | TGTX | Director | Nov 24, 2025 | Sell | $32.57 | 5,000 | $162,850.00 | 223,816 | |
| Lonial Sagar | TGTX | Director | Sep 11, 2025 | Sell | $32.24 | 20,852 | $672,268.48 | 94,061 |
Compare TGTX vs Leading Stocks
See how TGTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TGTX TG Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.